会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Compositions and methods for angiogenic therapy utilizing genes encoding ets-1
    • 使用编码ets-1的基因进行血管生成治疗的组合物和方法
    • US07994151B2
    • 2011-08-09
    • US12435335
    • 2009-05-04
    • Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
    • Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
    • A61K48/00A01N63/00A01N65/00C12N15/00C07H21/04
    • A61K38/52A61K31/5585A61K31/711A61K38/1709A61K38/1833A61K38/1858A61K48/00A61K2300/00
    • The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
    • 本发明提供:(1)血管生成治疗用药物组合物,其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分,以及生成它们的物质; 和编码血管生成因子的基因; (2)增强编码血管生成因子的基因的血管生成作用的药剂,其含有选自具有血管舒张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; (3)含有前列环素合酶基因作为活性成分的血管生成剂; (4)含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; (4)含有ets1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和(5)含有ets-1基因作为活性成分的血管生成剂。
    • 2. 发明申请
    • Pharmaceutical Compositions for Angiogenic Therapy
    • 血管生成治疗药物组合物
    • US20100240735A1
    • 2010-09-23
    • US12435335
    • 2009-05-04
    • Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
    • Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
    • A61K31/7088A61P9/10
    • A61K38/52A61K31/5585A61K31/711A61K38/1709A61K38/1833A61K38/1858A61K48/00A61K2300/00
    • The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
    • 本发明提供:(1)血管生成治疗用药物组合物,其含有选自具有血管扩张作用和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分,以及生成它们的物质; 和编码血管生成因子的基因; (2)增强编码血管生成因子的基因的血管生成作用的药剂,其含有选自具有血管舒张作用和/或血小板聚集抑制作用的物质和/或血小板聚集抑制作用的物质中的至少一种物质作为活性成分; (3)含有前列环素合酶基因作为活性成分的血管生成剂; (4)含有ets-1基因和编码血管生成因子的另一基因作为活性成分的用于血管生成治疗的药物组合物; (4)含有ets1基因作为增强编码血管生成因子的另一基因的血管生成作用的活性成分的药剂; 和(5)含有ets-1基因作为活性成分的血管生成剂。
    • 5. 发明授权
    • Chimera (double) decoy
    • 嵌合(双)诱饵
    • US08067384B2
    • 2011-11-29
    • US11662777
    • 2005-10-20
    • Ryuichi MorishitaToshio OgiharaMotokuni AokiTakashi Miyake
    • Ryuichi MorishitaToshio OgiharaMotokuni AokiTakashi Miyake
    • C12N15/11C12N15/113C12N15/115
    • C12N15/113A61K48/00C12N2310/13C12N2310/3519
    • The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.
    • 本发明提供了一种用于血管再狭窄,缺血性疾病,过敏性疾病,炎性疾病,自身免疫性疾病或癌症转移,侵袭(癌症转移/侵袭)或恶病质的预防,改善或治疗药物,其基于对多种转录的抑制作用 监管因素。 本发明的嵌合体(双)诱饵在其单个分子中具有多个转录调节因子结合序列。 因此,能够用单个分子抑制多个转录调节因子的活性。 例如,人造血管的吻合部位的狭窄是由血管内膜的增厚引起的,这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。 因此,通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子,可以抑制血管壁的增厚。
    • 7. 发明申请
    • Chimeric (Double) Decoy
    • 嵌合(双)诱饵
    • US20070259826A1
    • 2007-11-08
    • US11662777
    • 2005-10-20
    • Ryuichi MorishitaToshio OgiharaMotokuni AokiTakashi Miyake
    • Ryuichi MorishitaToshio OgiharaMotokuni AokiTakashi Miyake
    • A61K31/713A61K31/70A61K31/7105A61P17/06A61P35/04A61P41/00C07H21/02C07H21/04A61P9/10A61P37/08A61P29/00A61P17/00A61K31/711
    • C12N15/113A61K48/00C12N2310/13C12N2310/3519
    • The present invention provides a prophylactic, ameliorative or therapeutic medicament for vascular restenosis, ischemic disease, allergic disease, inflammatory disease, autoimmune disease, or cancer metastasis, invasion (cancer metastasis/invasion) or cachexia based on the inhibitory action on a plural of transcriptional regulatory factor. A chimera (double) decoy of the present invention has plural transcriptional regulatory factor binding sequences in a single molecule thereof. Thus, it is able to inhibit the activity of plural transcriptional regulatory factors with a single molecule. For example, stenosis of an anastomosed site of an artificial blood vessel is caused by thickening of the vascular intima, and this is mainly caused by activation of cell proliferation by an inflammatory reaction occurring at the anastomosed site. Thus, thickening of vessel walls can be inhibited by simultaneously inhibiting two transcriptional regulatory factors involved in inflammation and cell proliferation by using the chimera decoy of the present invention.
    • 本发明提供了一种用于血管再狭窄,缺血性疾病,过敏性疾病,炎性疾病,自身免疫性疾病或癌症转移,侵袭(癌症转移/侵袭)或恶病质的预防,改善或治疗药物,其基于对多种转录的抑制作用 监管因素。 本发明的嵌合体(双)诱饵在其单个分子中具有多个转录调节因子结合序列。 因此,能够用单个分子抑制多个转录调节因子的活性。 例如,人造血管的吻合部位的狭窄是由血管内膜的增厚引起的,这主要是由在吻合部位发生的炎性反应的细胞增殖的激活引起的。 因此,通过使用本发明的嵌合体诱饵同时抑制涉及炎症和细胞增殖的两种转录调节因子,可以抑制血管壁的增厚。